TTNP Titan Pharmaceuticals
- 6.7183
- +0.0425+0.64%
Titan Pharmaceuticals News
Titan Pharmaceuticals (TTNP.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $98,000; earnings per share of -$1.24, previous value of -$2.20.
Titan Pharmaceuticals (TTNP.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $98,000; earnings per share of -$1.24, previous value of -$2.20.
10-Q: Quarterly report
12 Health Care Stocks Moving In Monday's Intraday Session
GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
Titan Pharmaceuticals Files FormRW Co Decided Not To Pursue The Offering Due To Market Conditions And No Longer Wishes To Conduct A Public Offering Of Securities At This Time, No Securities Covered By The Registration Statement Have Been Issued Or Sold.
Titan Pharmaceuticals Files FormRW Co Decided Not To Pursue The Offering Due To Market Conditions And No Longer Wishes To Conduct A Public Offering Of Securities At This Time, No Securities Covered By
12 Health Care Stocks Moving In Friday's After-Market Session
GainersMobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion. Galera Therapeutics (NASDAQ:GRTX) stock in
Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical Among Healthcare Movers
The Sire Group Ltd Says Expect To Propose To Titan Pharmaceuticals Inc A Business Combination With KE Sdn. Bhd
- SEC 13D/Amended FilingAfter giving effect to these changes in membership, as of April 2, 2024, four of the board's seven directors had been nominated by the reporting persons. The reporting persons
Titan Pharmaceuticals Overhauls Leadership, Settles With Ex-Directors
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. Fresh2 Group
Community Pharmacies Back In Business After Distributor Cutoffs Thanks To TITAN
RANDOLPH, N.J., March 20, 2024 /PRNewswire/ -- You own a small community pharmacy. One day the phone rings and your pharmaceutical supplier announces that your store has been cut off due to a possibl
WIMI, TTNP and STI Among Mid-day Movers
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersApplied DNA Sciences (NASDAQ:APDN) stock moved upwards by 33.1% to $0.49 during Monday's pre-market session. The market value of their outstanding shares is at $8.3 million. XTL Biopharmaceutic
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersChina SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market cap stands at $2.2 million. Titan Pharma (NASDAQ:TTNP) stock moved
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that by letter dated January 24, 2024, the Company was notified by The
TTNP, SLDB and WRAP Among Mid-day Movers
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Analysis
Price Target
No Data
